Lazard Asset Management
ACRS icon

Lazard Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Lazard Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-32,900
Closed -$811K – 1033
2017
Q4 		$811K Sell
32,900
-13,900
-30% -$338K ﹤0.01% 719
2017
Q3 		$1.21M Hold
46,800
– – ﹤0.01% 664
2017
Q2 		$1.27M Sell
46,800
-1,600
-3% -$43.5K ﹤0.01% 649
2017
Q1 		$1.44M Buy
+48,400
New +$1.4M ﹤0.01% 681

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Lazard Asset Management's ACRS Position: Q1 2018 in Review

Lazard Asset Management sold out of Aclaris Therapeutics (ACRS) in Q1 2018, closing a stake of 32,900 shares — an estimated $811K sold.

Lazard Asset Management first reported a position in ACRS in Q1 2017 and held it in 4 quarters. The position peaked at $1.44M in Q1 2017. 100 funds tracked by Wall St. Rank hold ACRS as of Q1 2018.

  • Lazard Asset Management reported no remaining Aclaris Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Lazard Asset Management sold 32,900 Aclaris Therapeutics shares in Q1 2018, an estimated $811K.
  • Lazard Asset Management first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 4 quarters.
  • Lazard Asset Management's Aclaris Therapeutics position peaked at $1.44M in Q1 2017.
  • 100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2018.

Based on Lazard Asset Management's 13F filing for Q1 2018, filed 14 May 2018.